Latest Headlines
-
University Of California, Irvine, Verifies GATC Health's Ability To Predict Drug Efficacy, Safety And Off-Target Effects
5/16/2024
GATC Health Corp, a technology company advancing drug discovery and disease prediction using artificial intelligence (AI), has successfully completed two external AI platform validation tests in collaboration with a pharmaceutical science lab at University of California, Irvine's (UCI).
-
Parallel Bio Launches Clinical Trial In A Dish To Speed Drug Discovery
5/16/2024
Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and safety of new immunotherapies using human models at the earliest stages of drug discovery.
-
Sartorius To Advance Drug Discovery And Manufacturing With AI In Collaboration With NVIDIA
5/16/2024
The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software.
-
XtalPi To Host Inaugural Symposium On The Acceleration Of Drug Discovery Through The Use Of AI, Automation, And Digitalization
5/15/2024
XtalPi Inc. (XtalPi), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of medicines and innovative materials, announced it will host XtalPi Tech Talks, a one-day symposium on June 6, 2024, in Boston, Massachusetts.
-
Novel Inhibitor Insights Offer Pathway To Preventing PXR-Associated Drug Resistance
5/14/2024
Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs.
-
A New Drug Shows Potential Benefits In The Recovery Of Patients After A Heart Attack
5/14/2024
Researchers from the Cardiac Regeneration and Heart Failure Research Group (ICREC) at the Germans Trias i Pujol Research Institute (IGTP) and the Heart Institute of the Germans Trias Hospital (iCor) have found beneficial effects of the novel drug Sacubitril/Valsartan in the management of myocardial infarction (MI).
-
CENTOGENE And Evotec Discover Promising New Molecule To Treat Gaucher Disease
5/14/2024
Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the discovery of a new small molecule together with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO).
-
Sumitomo Pharma Announces FDA Acceptance Of Supplemental New Drug Application For Vibegron In Men With Overactive Bladder Symptoms Receiving Pharmacological Therapy For Benign Prostatic Hyperplasia
5/13/2024
Sumitomo Pharma America, Inc. (SMPA), announced today the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for vibegron (GEMTESA®), a beta-3 adrenergic receptor (β3) agonist, dosed once-daily (75 mg), for the treatment of men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH).
-
Ajax Therapeutics Announces FDA Clearance Of IND Application For AJ1-11095, A First-In-Class Type II JAK2 Inhibitor, For The Treatment Of Myelofibrosis
5/13/2024
Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1clinical study of AJ1‑11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis.
-
Certara & Cloudscientific Accelerate AI For Drug Development In China
5/10/2024
Certara, Inc., a global leader in model-informed drug development (MIDD), today announced a new distributor agreement with Cloudscientific.